|Bid||0.64 x 0|
|Ask||0.66 x 0|
|Day's Range||0.6400 - 0.7200|
|52 Week Range||0.5000 - 1.5000|
|Beta (3Y Monthly)||0.74|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BEVERLY, Mass., Feb. 12, 2019 -- LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen.
BEVERLY, Mass., Feb. 07, 2019 -- LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen.
TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that it has started a clinical study to collect data using its LX genetic analyzer technology. LexaGene is using frozen samples that were collected from dogs suspected of having a UTI. These frozen samples are being provided by Ethos Veterinary Health Group. LexaGene’s scientists are loading thawed samples on to the Company’s automated genetic analyzer for testing. Prior to sending the samples to LexaGene, Ethos shipped duplicate samples to their standard reference laboratory for testing so that LexaGene can compare their generated data to the current method.
TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that the Company has formed a scientific advisory board (SAB) to assist the Company in product positioning and its go-to-market strategy. The SAB is comprised of key opinion leaders in the Company’s targeted markets, namely food safety, veterinary diagnostics, and open-access markets such as biodefense. The initial SAB members include Dr. Kimothy Smith DVM PhD and Mr. Shawn Stevens JD. Other SAB members will be added over the coming months to complete a five-member advisory board.
TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation and assays for pathogen detection, today announced that the Company was featured on ABC-affiliated television station WCVB Boston on a segment of ‘Cutting Edge’ on December 21, 2018. “We were very honored to be featured in ABC’s ‘Cutting Edge’ Program and to have the opportunity to showcase LexaGene’s vision and the impact this technology can have on the world. To help solve this problem, LexaGene is developing a low-cost – yet extremely sensitive – pathogen detection instrument that will provide food safety officers at food processing and packaging facilities with a more rapid assessment on the safety of their products,” states Dr. Jack Regan, LexaGene’s CEO and Founder.
TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation and assays for pathogen detection, today announced the completion of a syndromic panel to detect urinary tract infection (UTI) in small animals. The assay is capable of detecting each of the eight most common pathogens responsible for the majority (95%) of all clinical canine UTI cases. LexaGene's UTI panel is designed to detect the causative pathogens with greater sensitivity and specificity than traditional culture-based detection which is prone to false positive results. Currently, in the US alone, there are 90 million dogs, with an estimated 5.4 million tests performed for urinary tract infections. These infections can be caused by at least 69 different pathogens, but 95% of these infections are caused by just 8 pathogens.
DHS was founded in response to the September 11th attacks and the bioterrorist attacks on September 18th in 2001 when anonymous letters laced with deadly anthrax spores were delivered to media companies and congressional offices resulting in five deaths and 17 others being infected. Since these events, DHS has supported and implemented proven technologies into their BioWatch Program to better detect bioterrorist attacks. Dr. Jack Regan, LexaGene’s CEO and Founder, previously worked at Lawrence Livermore National Laboratory developing a DHS-funded Autonomous Pathogen Detection System (APDS). This system was designed to automatically screen the air for weaponized bacteria. After its completion, the APDS system was validated by DHS and became an active component of their BioWatch Program, where it operated 24/7 providing autonomous surveillance. Despite the successes of the system, Dr. Regan’s experience developing this technology motivated him to design a next-generation genetic analyzer that would be more powerful than the APDS system and have uses beyond those of biodefense. The results of these efforts are now being realized through LexaGene’s development of the LX2™ Genetic Analyzer.
TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, today announced that following the most recent widespread multi-state recall of romaine lettuce contaminated with E.coli, and a food safety alert from the Centers for Disease Control (CDC) declaring all romaine lettuce unsafe to eat, LexaGene has been voted among the “10 Most Promising Food and Beverages Solution Providers 2018” by CIOReview based on the Company’s pathogen detection system, the LX2™ Genetic Analyzer.
VANCOUVER , July 11, 2018 /CNW/ - LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") has closed its previously announced bought deal offering of units (the "Offering") for aggregate gross proceeds of $5.75 million . In connection with this closing the underwriters exercised the over-allotment option in full. As a result, the Company issued 5,750,000 units at a price of $1.00 per unit, each unit consisting of one common share and one –half of one common share purchase warrant. Each whole warrant entitles the holder to purchase, subject to adjustment in certain circumstances, one additional common share at a price of $1.30 per common share until July 11, 2021 . The financing was led by Canaccord Genuity Corp. and included Echelon Wealth Partners Inc. The Company issued to the underwriters an aggregate of 402,500 compensation warrants, each compensation warrant entitling the holder to purchase one common share of the Company at a price of $1.00 per share until July 11, 2021 .
VANCOUVER , June 19, 2018 /CNW/ - LexaGene Holdings Inc. (TSX VENTURE: LXG) ("LexaGene" or the "Company") is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Canaccord Genuity Corp. (the "Underwriters") pursuant to which the Underwriters have agreed to purchase, on a bought deal basis subject to the filing of a short form prospectus, an aggregate of 5,000,000 units (the "Units") at a price of $1.00 per Unit (the "Offering Price") for aggregate gross proceeds to LexaGene of $5,000,000 (the "Offering"). Each Unit will consist of one common share of the Company (a "Common Share") and one half of one Common Share purchase warrant (each whole Common Share purchase warrant, a "Warrant").